| scholarly article | Q13442814 |
| P2093 | author name string | Nobuhiko Katunuma | |
| Naozumi Ishimaru | |||
| Ichiro Saito | |||
| Kumiko Yanagi | |||
| Yoshio Hayashi | |||
| Rieko Arakaki | |||
| Kaoru Saegusa | |||
| Kouichi Ogawa | |||
| P2860 | cites work | Human cathepsin S: chromosomal localization, gene structure, and tissue distribution | Q24310666 |
| Increased fluid secretion after adenoviral-mediated transfer of the aquaporin-1 cDNA to irradiated rat salivary glands | Q24312174 | ||
| Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading | Q24328923 | ||
| Molecular definition and sequence motifs of the 52-kD component of human SS-A/Ro autoantigen | Q24595305 | ||
| Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages | Q24676370 | ||
| Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L | Q24678337 | ||
| Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease | Q28117779 | ||
| A new animal model for primary Sjögren's syndrome in NFS/sld mutant mice | Q28504572 | ||
| Estrogen deficiency accelerates autoimmune exocrinopathy in murine Sjögren's syndrome through fas-mediated apoptosis | Q28505200 | ||
| Effector mechanism of experimental autoimmune sialadenitis in the mouse model for primary Sjögren's syndrome | Q28506373 | ||
| Identification of alpha-fodrin as a candidate autoantigen in primary Sjögren's syndrome | Q28587895 | ||
| Severe destructive autoimmune lesions with aging in murine Sjögren's syndrome through Fas-mediated apoptosis | Q28590287 | ||
| Cathepsin S required for normal MHC class II peptide loading and germinal center development | Q28611850 | ||
| Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus | Q28613227 | ||
| Role for intracellular proteases in the processing and transport of class II HLA antigens | Q33578498 | ||
| Bioenergetics of immune functions: fundamental and therapeutic aspects | Q33877011 | ||
| Stimulation of T cells by antigen-presenting cells is kinetically controlled by antigenic peptide binding to major histocompatibility complex class II molecules | Q34499456 | ||
| A new mutation involving the sublingual gland in NFS/N mice. Partially arrested mucous cell differentiation | Q35818863 | ||
| Early biochemical signals arise from low affinity TCR-ligand reactions at the cell-cell interface | Q36367143 | ||
| Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism | Q36380525 | ||
| Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation | Q36475793 | ||
| Specific T cell recognition of kinetic isomers in the binding of peptide to class II major histocompatibility complex | Q36555812 | ||
| Cathepsin S activity regulates antigen presentation and immunity | Q37382422 | ||
| Sjögren's syndrome. Proposed criteria for classification | Q39790521 | ||
| Antigen presentation. Getting peptides into MHC class II molecules | Q40629975 | ||
| MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation | Q40807437 | ||
| Diagnostic criteria and immunopathogenesis of Sjögren's syndrome: implications for therapy | Q40957254 | ||
| How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway | Q41020969 | ||
| Class II antigen expression by lacrimal epithelial cells. An updated working hypothesis for antigen presentation by epithelial cells | Q41152601 | ||
| Inhibition of endosomal proteolytic activity by leupeptin blocks surface expression of MHC class II molecules and their conversion to SDS resistance alpha beta heterodimers in endosomes | Q41515448 | ||
| Structural analysis of proteolytic products of MHC class II-invariant chain complexes generated in vivo. | Q41520444 | ||
| Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells | Q41561517 | ||
| Assembly and transport properties of invariant chain trimers and HLA-DR-invariant chain complexes | Q41621208 | ||
| Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain | Q41653246 | ||
| Cathepsin B cleavage of Ii from class II MHC alpha- and beta-chains | Q41680884 | ||
| MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding | Q41941589 | ||
| Inhibition by leupeptin and antipain of the intracellular proteolysis of Ii. | Q41946100 | ||
| HLA class II induction in human islet cells by interferon-γ plus tumour necrosis factor or lymphotoxin | Q59083904 | ||
| TNF is here to stay! | Q61819239 | ||
| Class II MHC antigen expression on epithelial cells of salivary glands from patients with Sjögren's syndrome | Q68835769 | ||
| Induction of experimental autoallergic sialadenitis | Q69126226 | ||
| Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro | Q70136099 | ||
| Novel epoxysuccinyl peptides. A selective inhibitor of cathepsin B, in vivo | Q70136102 | ||
| Expression of histocompatibility antigen HLA-DR by salivary gland epithelial cells in Sjögren's syndrome | Q70304887 | ||
| Participation of cathepsin B in processing of antigen presentation to MHC class II | Q70494348 | ||
| Specific assay method for the activities of cathepsin L-type cysteine proteinases | Q72411002 | ||
| Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity | Q72565150 | ||
| Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo | Q73077056 | ||
| Autoantigen-specific CD4+CD28low T cell subset prevents autoimmune exocrinopathy in murine Sjögren's syndrome | Q74108365 | ||
| Mechanisms of neonatal tolerance induced in an animal model for primary Sjögren's syndrome by intravenous administration of autoantigen | Q74267251 | ||
| Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice | Q74595052 | ||
| Fas ligand-mediated exocrinopathy resembling Sjögren's syndrome in mice transgenic for IL-10 | Q74595808 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Mucin 19 | Q21985138 |
| Cathepsin S | Q22677356 | ||
| P304 | page(s) | 361–369 | |
| P577 | publication date | 2002-08-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity | |
| P478 | volume | 110 |
| Q37228071 | A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjögren's syndrome |
| Q34391184 | Amino acid substitutions in the thyroglobulin gene are associated with susceptibility to human and murine autoimmune thyroid disease |
| Q33670454 | Anti-inflammatory effects of rebamipide eyedrop administration on ocular lesions in a murine model of primary Sjögren's syndrome |
| Q92382240 | Cathepsin G and Its Role in Inflammation and Autoimmune Diseases |
| Q33705115 | Cathepsin L Inhibition Prevents Murine Autoimmune Diabetes via Suppression of CD8+ T Cell Activity |
| Q34014524 | Cathepsin L is essential for onset of autoimmune diabetes in NOD mice |
| Q33765990 | Cathepsin S inhibition combines control of systemic and peripheral pathomechanisms of autoimmune tissue injury. |
| Q51719566 | Cathepsin S inhibition lowers blood glucose levels in mice. |
| Q46803900 | Cathepsin S is not crucial to TSHR processing and presentation in a murine model of Graves' disease |
| Q37294866 | Cathepsins and their endogenous inhibitors cystatins: expression and modulation in multiple sclerosis |
| Q39593840 | Coordinated involvement of cathepsins S, D and cystatin C in the commitment of hematopoietic stem cells to dendritic cells. |
| Q91997273 | Differential effects of specific cathepsin S inhibition in biocompartments from patients with primary Sjögren syndrome |
| Q34310225 | Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm |
| Q34600485 | Expression of the retinoblastoma protein RbAp48 in exocrine glands leads to Sjögren's syndrome-like autoimmune exocrinopathy |
| Q35621386 | Fluorescent probes for proteolysis: tools for drug discovery |
| Q36996406 | GILT expression in B cells diminishes cathepsin S steady-state protein expression and activity |
| Q30781352 | Imbalanced Rab3D versus Rab27 increases cathepsin S secretion from lacrimal acini in a mouse model of Sjögren's Syndrome |
| Q28084887 | Immunological function of Blimp-1 in dendritic cells and relevance to autoimmune diseases |
| Q62398516 | Increased Cathepsin S activity associated with decreased protease inhibitory capacity contributes to altered tear proteins in Sjögren's Syndrome patients |
| Q34735358 | Increased expression of cathepsins and obesity-induced proinflammatory cytokines in lacrimal glands of male NOD mouse |
| Q91565357 | Inhibition of Cathepsin S Reduces Lacrimal Gland Inflammation and Increases Tear Flow in a Mouse Model of Sjögren's Syndrome |
| Q41140614 | Interferon-γ treatment in vitro elicits some of the changes in cathepsin S and antigen presentation characteristic of lacrimal glands and corneas from the NOD mouse model of Sjögren's Syndrome |
| Q26997316 | Intracellular nucleic acid sensors and autoimmunity |
| Q24799214 | Local expression of matrix metalloproteinases, cathepsins, and their inhibitors during the development of murine antigen-induced arthritis |
| Q62398515 | Longitudinal analysis of tear cathepsin S activity levels in male non-obese diabetic mice suggests its potential as an early stage biomarker of Sjögren's Syndrome |
| Q33653232 | Lymphocytic infiltration leads to degradation of lacrimal gland extracellular matrix structures in NOD mice exhibiting a Sjögren's syndrome-like exocrinopathy |
| Q93064841 | Lysosomes as a therapeutic target |
| Q35622999 | Manipulating autophagic processes in autoimmune diseases: a special focus on modulating chaperone-mediated autophagy, an emerging therapeutic target |
| Q37973268 | Microbial and fungal protease inhibitors--current and potential applications |
| Q38783180 | Mycobacterium bovis BCG Interferes with miR-3619-5p Control of Cathepsin S in the Process of Autophagy |
| Q62398517 | NOD and NOR mice exhibit comparable development of lacrimal gland secretory dysfunction but NOD mice have more severe autoimmune dacryoadenitis |
| Q33838722 | Pathological Analysis of Ocular Lesions in a Murine Model of Sjögren's Syndrome |
| Q37610134 | Rapamycin Eye Drops Suppress Lacrimal Gland Inflammation In a Murine Model of Sjögren's Syndrome. |
| Q26774797 | SLE-associated risk factors affect DC function |
| Q34598268 | Structure-based development of specific inhibitors for individual cathepsins and their medical applications |
| Q33831656 | Tear cathepsin S as a candidate biomarker for Sjögren's syndrome |
| Q37223894 | The immunomodulatory action of sialostatin L on dendritic cells reveals its potential to interfere with autoimmunity |
| Q36088877 | Unmet medical needs in lupus nephritis: solutions through evidence-based, personalized medicine |
| Q35027428 | “Venopathy” at work: recasting neointimal hyperplasia in a new light |
Search more.